BLA 761420 · Celltrion INC
Avtozma
Tocilizumab-Anoh · Intravenous, Subcutaneous · Interleukin-6 Receptor Antagonist
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Jan 24, 2025
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
497
158 Phase 3, 67 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Tocilizumab" as an intervention, any sponsor and status, largest first.
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk FactorsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01331837 · 3,080 participants · Start Aug 2, 2011 · Primary completion Mar 25, 2016
Drug: Etanercept; Tocilizumab · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Tuscaloosa, Alabama · 428 sites in all
- An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core StudiesPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00720798 · 2,067 participants · Start Sep 2005 · Primary completion Apr 2013
Drug: Tocilizumab; Disease-modifying anti-rheumatic drugs and 2 more · For: Rheumatoid Arthritis
Sites: Birmingham, Alabama; Huntsville, Alabama; Mesa, Arizona · 295 sites in all
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialPivotal-lookingRecruiting
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT06381661 · 2,000 participants (planned) · Start Jul 9, 2026 · Primary completion Aug 9, 2028
Drug: Tocilizumab; Baricitinib and 13 more · For: Sepsis
Sites: Dijon, France; Étampes, France; Garches, France · 19 sites in all
- The Fleming [FMTVDM] Directed CoVid-19 Treatment ProtocolPivotal-lookingCompleted
The Camelot FoundationAcademic, hospital or other
NCT04349410 · 1,800 participants · Start Apr 11, 2020 · Primary completion Sep 14, 2020
Drug: Hydroxychloroquine, Azithromycin; Hydroxychloroquine, Doxycycline and 9 more · For: CoVid 19 Positive
Sites: Los Angeles, California
- An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy.Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00750880 · 1,681 participants · Start Sep 2008 · Primary completion Jul 2011
Drug: tocilizumab [RoActemra/Actemra] · For: Rheumatoid Arthritis
Sites: Canberra, Australia; Coffs Harbour, Australia; Kogarah, Australia · 282 sites in all
- A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid ArthritisPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01194414 · 1,262 participants · Start Sep 2010 · Primary completion Jan 2012
Drug: tocilizumab SC; tocilizumab IV and 3 more · For: Rheumatoid Arthritis
Sites: Huntsville, Alabama; Tuscaloosa, Alabama; Tucson, Arizona · 216 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Khanna D, Lin CJF, Furst DE, et al. · Lancet Respir Med 2020 · Clinical Trial, Phase III, Multicenter Study
- Trial of Tocilizumab in Giant-Cell Arteritis.
Stone JH, Tuckwell K, Dimonaco S, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Comparative Study
- Tocilizumab in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis.
Ghazipura M, Macrea M, Herman D, et al. · Ann Am Thorac Soc 2024 · Meta-Analysis, Systematic Review
- Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease.
Roofeh D, Lin CJF, Goldin J, et al. · Arthritis Rheumatol 2021 · Clinical Trial, Phase III, Randomized Controlled Trial
- Efficacy and safety of biologic drugs in Still's disease: a systematic review and network meta-analysis of randomized controlled trials.
Kilic B, Ozturk A, Karup S, et al. · Rheumatology (Oxford) 2025 · Systematic Review, Network Meta-Analysis
- Tocilizumab Monotherapy or Combined With Methotrexate for Rheumatoid Arthritis: A Randomized Clinical Trial.
Liu T, Wang L, Zhang X, et al. · JAMA Netw Open 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Celltrion INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.